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Vascular Medicine
Identification of a Danger-Associated Peptide From
Apolipoprotein B100 (ApoBDS-1) That Triggers Innate
Proatherogenic Responses
Daniel F.J. Ketelhuth, PhD*; Francisco J.O. Rios, PhD*; Yajuan Wang, MD; Huiqing Liu, PhD;
Maria E. Johansson, PhD; Gunilla N. Fredrikson, PhD; Ulf Hedin, MD, PhD; Magnus Gidlund, PhD;
Jan Nilsson, MD, PhD; Go¨ran K. Hansson, MD, PhD; Zhong-qun Yan, MD, PhD
Background—Subendothelial deposited low-density lipoprotein particles are a known inflammatory factor in atheroscle-
rosis. However, the causal components derived from low-density lipoprotein are still poorly defined. Apolipoprotein
B100 (ApoB100) is the unexchangeable protein component of low-density lipoprotein, and the progression of
atherosclerosis is associated with immune responses to ApoB100-derived peptides. In this study, we analyzed the
proinflammatory activity of ApoB100 peptides in atherosclerosis.
Methods and Results—By screening a peptide library of ApoB100, we identified a distinct native peptide referred to as
ApoB100 danger-associated signal 1 (ApoBDS-1), which shows sequence-specific bioactivity in stimulation of
interleukin-8, CCL2, and interleukin-6. ApoBDS-1 activates mitogen-activated protein kinase and calcium signaling,
thereby effecting the expression of interleukin-8 in innate immune cells. Ex vivo stimulation of carotid plaques with
ApoBDS-1 enhances interleukin-8 and prostaglandin E2 release. Furthermore, we demonstrated that ApoBDS-1–
positive peptide fragments are present in atherosclerotic lesions using immunoassays and that low-molecular-weight
fractions isolated from plaque show ApoBDS-1 activity inducing interleukin-8 production.
Conclusions—Our data show that ApoBDS-1 is a previously unrecognized peptide with robust proinflammatory activity,
contributing to the disease-promoting effects of low-density lipoprotein in the pathogenesis of atherosclerosis.
(Circulation. 2011;124:2433-2443.)
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Low-density lipoprotein (LDL) is a complex particle thatcomprises triglycerides and cholesteryl ester molecules
in its core; unesterified cholesterol molecules, of which
approximately one third lie in the core and two thirds reside
on the surface; a surface monolayer of phospholipid mole-
cules; and a single copy of apolipoprotein B100 (ApoB100)
(4536 amino acids).1
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Retention of LDL in the subendothelial space of arteries is
a hallmark of the initial pathogenesis of atherosclerosis.2
Subsequently, the trapped LDL particles undergo various
biochemical modifications that are mediated by oxidative,
lipolytic, and proteolytic enzymes and reactive oxygen spe-
cies.3–5 Clinical and laboratory data have shown that modified
LDL instigates chronic inflammatory responses in the artery
wall, indicating that the modifications confer LDL with
bioactivities that effect initiation, progression, and com-
plications of atherosclerosis.6 For instance, modified phos-
pholipids of LDL, such as lysophosphatidylcholine and
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine
(POVPC), can stimulate endothelial cells, smooth muscle
cells, and macrophages.7,8 It is known now that such athero-
genic lipids initiate innate immune response through activa-
tion of Toll-like receptors.9–11 Collectively, these data imply
that modification of LDL generates endogenous ligands that
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trigger activation of the innate immune system that promotes
atherosclerosis.
Although the hypothesis that modification of LDL plays
a major role in the pathogenesis of atherosclerosis is well
established, recent reports have shown that native peptides
of ApoB100 trigger activation of adaptive immune
responses.12–14 Using a library of malondialdehyde-modified
or native polypeptides that encompassed the entire sequence
of ApoB100, Fredrikson et al15 recently identified 100
native peptides of ApoB100 that could be recognized by
circulating IgM or IgG autoantibodies from atherosclerotic
patients. Subsequent work demonstrated that such native
epitopes exist in carotid plaque, with nearly 3-fold higher
levels in plaques from individuals with clinical symptoms
than in asymptomatic individuals.16
To enhance our current understanding of the biological
activities of LDL in atherosclerosis, we determined whether
sequences of ApoB100 activate monocytes/macrophages. By
screening a peptide library of ApoB100, we identified a
peptide that had sequence-specific bioactivity, inducing in-
flammatory responses in innate immune cells and ex vivo
cultured carotid plaques by initiating mitogen-activated pro-
tein kinase (MAPK) and Ca2-dependent signaling pathways.
We have named this novel peptide ApoB100 danger-
associated signal 1 (ApoBDS-1).
Methods
For an expanded Methods section, please refer to the online-only
Data Supplement.
Screen of the ApoB100 Library
The screen for potential peptides was performed with the use of the
monocytic cell line THP-1 (TIB-202; ATCC, VA). Cells were
cultured in RPMI-1640 medium (Gibco Invitrogen, Carlsbad, CA)
that was supplemented with 10% (vol/vol) fetal calf serum (Sigma-
Aldrich, St Louis, MO), penicillin (100 U/mL)/streptomycin (100
g/mL) (Sigma-Aldrich), 2 mmol/L L-glutamine (Gibco Invitrogen),
15 mmol/L HEPES (Gibco Invitrogen), and 11 mmol/L sodium
bicarbonate (Sigma-Aldrich) and maintained in a humidified atmo-
sphere of 5% CO2 at 37°C. For the experiments, 2.5105 cells per
well were incubated in duplicate with each of native ApoB100
peptides.
Ex Vivo Stimulation of Atherosclerotic
Plaque Tissue
Eight carotid artery plaques were collected from patients who
were undergoing endarterectomy at Karolinska University Hos-
pital. Informed consent was obtained from all subjects. The
investigation was approved by the Ethical Committee of Northern
Stockholm and was in agreement with institutional guidelines and
the principles that have been set forth in the Declaration of
Helsinki.
Fresh plaques were processed to remove calcified tissue, cut into
small pieces (2 mm3), and washed with cold phosphate-buffered
saline. The pieces were distributed equally in a 48-well plate (0.1
mg per well). Two to 4 hours after incubation in RPMI with 10%
fetal calf serum, the tissues were stimulated in duplicate for 24 hours
with the indicated concentrations of ApoBDS-1.
Immunofluorescent Detection of ApoBDS-1 in
Carotid Atherosclerotic Plaques
For detection of ApoBDS-1, an affinity-purified rabbit IgG anti-
ApoBDS-1 antibody was generated (Anaspec, San Jose, CA). The
reactivity was verified against a set of ApoB100 peptides, demon-
strating high specificity to ApoBDS-1 (Figure I in the online-only
Data Supplement). Immunofluorescent staining for ApoBDS-1 was
performed on acetone-fixed frozen sections from 4 carotid endarter-
ectomy plaques with the use of the ApoBDS-1 antibody, followed by
DyLight 594 anti-rabbit IgG antibody (Vector Laboratories, Burlin-
game, CA). Sections from each plaque were costained with mono-
clonal antibody against human smooth muscle -actin (M0851;
Dako, Glostrup, Denmark), monoclonal antibody against human von
Willebrand factor (M0616; Dako), or monoclonal antibody against
human CD68 (556059; BD Biosciences, Franklin Lakes, NJ). Images
were captured with a Leica TCS SP5 confocal microscope (Leica,
Wetzlar, Germany).
As a specificity control, ApoBDS-1 peptide (20 g/mL) was
applied to the consecutive sections stained with ApoBDS-1 antibody.
The specific ApoBDS-1 signals were quantified. In brief, fluores-
cence per pixel was obtained by the conversion of images to
grayscale and a definition of global threshold with the use of Otsu’s
method.17 Total number of pixels above the threshold was calculated
with the use of Matlab software (MathWorks, MI).
Detection of ApoBDS-1 in Carotid
Plaque Homogenates
Plaques were rinsed in cold phosphate-buffered saline and disrupted
in cold T-PER tissue protein extraction reagent (Thermo Scientific,
MA) supplemented with Halt protease inhibitor cocktail and EDTA
(Thermo Scientific) with the use of an Ultraturrax homogenizer
(IKA-Labortechnik, Germany). Crude homogenates were centri-
fuged at 10 000g for 10 minutes, and the supernatant was used for
identification of ApoBDS-1. The protein content was determined by
Bradford (BioRad, LA).
For Western blot analysis of ApoBDS-1, samples were diluted
with Laemmli sample buffer (Bio-Rad), boiled, and loaded in
equal concentrations; 0.5g of ApoBDS-1 was included as a
positive control. Samples were separated by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred to a
polyvinylidene fluoride membrane (GE Healthcare, Uppsala,
Sweden) with the use of a semidry electrophoretic transfer cell at
125 mA for 45 minutes. ApoBDS-1– containing fragments were
detected with the use of the anti-ApoBDS-1 antibody (1.6
g/mL), followed with goat anti-rabbit IgG– horseradish peroxi-
dase (Dako), and visualized with an enhanced chemiluminescence
substrate (GE Healthcare).
For the chromatographic analysis, 2 mg of plaque homogenate
was fractionated with the use of an HR10/30 Superose 6 column
(GE Healthcare) and a Discovery BIO GFC-500 as precolumn (5
cm7.8 ID; Supelco, Sigma-Aldrich) coupled to a Prominence
ultrafast liquid chromatography system (Shimadzu, Kyoto, Japan)
and equilibrated with ammonium bicarbonate buffer, pH 7.4.
Forty-eight fractions of 500 L each were collected on a 96-well
enzyme-linked immunosorbent assay plate with a Foxy Jr fraction
collector (Teledyne Isco Inc, NE). Molecular weight calibration
of the system was performed (Figure II in the online-only Data
Supplement) with the use of high- and low-molecular-weight
calibration kits (GE Healthcare). To detect ApoBDS-1, 96-well
plates were coated overnight with the collected fractions, blocked
with 1% gelatin for 1 hour, and then incubated with anti-
ApoBDS-1 (1 g/mL) for 2 hours at room temperature. After they
were washed, the samples were incubated with horseradish
peroxidase– conjugated goat anti-rabbit antibody (Dako) and
developed with the use of 3,3,5,5-tetramethybenzidine (BD
Biosciences, Franklin Lakes, NJ). The absorbance was measured
with a microplate reader (VersaMax; Molecular Devices,
Sunnyvale, CA).
Assessment of the Activity of
ApoBDS-1–Positive Fractions
Chromatographic fractions from atherosclerotic plaque were ob-
tained as mentioned above. The collected fractions were resuspended
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in RPMI 1640 with 1% fetal calf serum and incubated with
peripheral blood mononuclear cells (PBMCs) (2.5105 cells per
well). For blocking experiments, PBMCs were preincubated with
p216c (60 g/mL) for 30 minutes. Levels of interleukin (IL)-8 in
supernatant were assessed after 24 hours of incubation by enzyme-
linked immunosorbent assay.
Statistical Analysis
Quantitative data are expressed as meanSEM. The nonparamet-
ric Mann-Whitney U test was used for 2-group comparisons, and
the Kruskal-Wallis test was used for multigroup comparisons.
Differences between groups were considered significant at
P0.05.
Results
Identification of ApoBDS-1 in ApoB100
To determine whether ApoB100-derived peptides have bio-
activity to stimulate monocyte/macrophages, THP-1 cells
were treated with 302 synthetic peptide of ApoB100. IL-8
secretion was used to reveal cell activation. At 25 g/mL, we
observed that at least 6 native peptides—P208, P211, P218,
P243, P292, and P216 (Table)—triggered IL-8 production
(Figure 1A).
To confirm these initial observations, the activity of
these peptides was examined in THP-1 cells. Among them,
P216 was the most effective peptide, eliciting dose-
dependent production of IL-8 (Figure 1B), and it was
termed ApoBDS-1.
During LDL oxidation, a common modification is the
addition of malondialdehyde adducts to the lysyl residues of
ApoB100.4 Notably, the modification of ApoBDS-1 with
malondialdehyde quenched its bioactivity (Figure 1C).
In addition to THP-1 cells (Figure 1B), primary cells from
blood were also examined. Human PBMCs (Figure 2A) and
monocyte-derived macrophages (Figure 2B) were more sen-
sitive to ApoBDS-1 than THP-1 cells, as evidenced by a
10-fold increase in IL-8 production. Consistent with its effect
on IL-8 production, ApoBDS-1 upregulated IL-8 mRNA
levels in PBMCs (Figure 2C). Collectively, these results
demonstrate that ApoBDS-1 is a distinct peptide of ApoB100
that has robust bioactivity, inducing IL-8 secretion by mono-
cytes and macrophages.
Because lipopolysaccharide is a widespread contaminant
of biochemical preparations and active at extremely low
concentrations, we determined whether the effect of
ApoBDS-1 was attributed to lipopolysaccharide contamina-
tion. Four independent batches of synthetic ApoBDS-1 were
tested, showing consistent activity throughout this study,
arguing against coincidental lipopolysaccharide contamina-
tion (data not shown). Furthermore, ApoBDS-1–induced IL-8
Table. Apolipoprotein B100 Peptide Sequences
Peptide ID
Amino Acid
Sequence
Position in Apolipoprotein
B100 Protein Sequence
P208 PEMRLPYTIITTPPLKDFSL aa 3106–3125
P211 KKNKHRHSITNPLAVLCEFI aa 3151–3170
P216 (ApoBDS-1) VPVVNVEVSPFTIEMSAFGY aa 3226–3245
P218 FSILGSDVRVPSYTLILPSL aa 3256–3275
P243 HLDIAGSLEGHLRFLKNIIL aa 3631–3650
P292 IVGWTVKYYELEEKIVSLIK aa 4366–4385
P216a VPVVNVEVSP aa 3226–3235
P216b VEVSPFTIEM aa 3232–3241
P216c FTIEMSAFGY aa 3236–3245
ApoBDS-1 indicates apolipoprotein B100 danger-associated signal 1.
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Figure 1. Identification of apolipoprotein
B100 danger-associated signal 1
(ApoBDS-1). A, THP-1 cells (2.5105)
were incubated in duplicate with 25
g/mL of each individual apolipoprotein
B100 peptide. Each bar represents the
interleukin (IL)-8 released in response to
the corresponding peptide. Medium alone
was used as negative control. B, Potential
bioactive peptides identified in A were
reevaluated. THP-1 cells (2.5105) were
incubated in duplicate with 12.5, 25, and
50 g/mL of peptides P208, P211, P216,
P218, P243, and P292. Data show
meanSEM. C, Malondialdehyde (MDA)
modification of P216 (ApoBDS-1). THP-1
cells (2.5105) were incubated in dupli-
cate with 40, 20, or 10 g/mL of native
and malondialdehyde-modified
ApoBDS-1.
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production was unaffected by the lipopolysaccharide inhibi-
tor polymyxin B, which suppressed 90% of lipopolysac-
charide-induced IL-8 levels (Figure 2D). In addition, IL-8
could not be induced by ApoBDS-1 in human embryonic
kidney cells that were stably transfected with Toll-like
receptor 4 (Figure 2E). These data demonstrate that activation
by ApoBDS-1 is not caused by lipopolysaccharide
contamination.
The Bioactivity of ApoBDS-1 Is
Sequence Dependent
To gain insights into its sequence-activity relationship,
ApoBDS-1 was truncated into 3 short fragments, each
consisting of 10 amino acids (Table). None of the trun-
cated fragments induced IL-8 production in PBMCs (Fig-
ure 2G). Furthermore, P215 and P217, the peptides flank-
ing on either end of ApoBDS-1 in the sequence of
ApoB100, were used as controls and failed to elicit IL-8
secretion (Figure 2G).
Effect of ApoBDS-1 on Induction of
Proinflammatory Mediators
To examine the function of ApoBDS-1 in the proinflamma-
tory response in greater detail, 10 additional chemokines and
cytokines were measured by cytometric bead array in the
supernatants of PBMCs that were incubated with ApoBDS-1
for 6 and 24 hours (Figure 3). IL-6 (Figure 3A) was rapidly
induced by ApoBDS-1 at 6 hours, followed by IL-8 and
CCL2 (monocyte chemotactic protein-1) production at 24
hours (Figure 3B). There was no effect, however, on IL-1,
tumor necrosis factor-, IL-12p70, interferon-, IL-10,
CXCL10 (IP-10), or CXCL9 (MIG) (Figure 3). These data
suggest that ApoBDS-1 influences a subset of inflammatory
mediators, including an unexpected downregulation of CCL5
release after 24 hours of treatment (Figure 3B).
ApoBDS-1 Increases Calcium Flux and
MAPK Phosphorylation
Next we explored the signaling mechanisms implicated in the
ApoBDS-1–induced cytokine and chemokine responses. Cal-
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Figure 2. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1)–dependent secretion of interleukin (IL)-8 is sequence spe-
cific and independent of Toll-like receptor 4 (TLR4). Peripheral blood mononuclear cells (4 donors) (A) and monocyte-derived
macrophages (4 donors) (B) were stimulated with ApoBDS-1 (25 g/mL) for 24 hours. IL-8 production was measured by enzyme-
linked immunosorbent assay; data are meanSEM. *P0.05, **P0.01 compared with control. C, mRNA levels of IL-8 were mea-
sured in peripheral blood mononuclear cells after 5 hours of incubation. Data are meanSEM of IL-8 mRNA levels of peripheral
blood mononuclear cells from 4 donors. **P0.01 compared with control. D, THP-1 cells (2.5105) were stimulated with
ApoBDS-1 (25 g/mL) and lipopolysaccharide (LPS) (100 ng/mL) in the presence or absence of polymyxin B (10 g/mL). IL-8 in
supernatant was measured after 24 hours. Results show meanSEM and are representative of 2 independent experiments.
Human embryonic kidney-293/TLR4 (E) or human embryonic kidney-293 (F) cells, respectively, were stimulated with lipopolysac-
charide (100 ng/mL) or ApoBDS-1 (25 g/mL). IL-8 in the supernatant was measured after 24 hours. Data are meanSEM of 4
independent experiments. G, Peripheral blood mononuclear cells (2.5105) were incubated with ApoBDS-1 (25 g/mL) or the
same concentration of truncated ApoBDS-1 (P216a, P216b, and P216c), P215, P217, or lipopolysaccharide (100 ng/mL). Super-
natant IL-8 was measured after 24 hours. Data are meanSEM of 4 donors.
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cium signaling is critical for the activation of transcriptional
regulatory pathways that underlie inflammatory and immune
responses.18
We observed that PBMCs responded to ApoBDS-1 by a
rapid increase in Ca2 flux within 30 seconds (Figure 4A and
4B) and subsequent slow decline over 240 seconds, with
leveling off (Figure 4B). Importantly, ApoBDS-1–induced
IL-8 production was completely abolished in the presence of
the calcium chelator 1,2-bis(2-aminophenoxy) ethane-
N,N,N,N-tetraacetic acid (BAPTA) (Figure 4C), indicating
that Ca2 flux is an early but also a critical signaling
mechanism in the course of ApoBDS-1–triggered IL-8
production.
Because Ca2 signaling is implicated in the modula-
tion of MAPK pathways, we examined the response
of MAPKs in THP-1 cells treated with ApoBDS-1. Activa-
ted ERK1/2 and JNK were evident 10 minutes and 60
minutes after ApoBDS-1 stimulation (Figure 4D). p38,
however, responded in a distinct manner characterized by
gradually activating over time and peaking at 60 minutes
(Figure 4D).
Next MAPK inhibitors were used to determine the role of
MAPKs in ApoBDS-1–induced IL-8 production. Pretreat-
ment of PBMCs with the ERK1/2 specific inhibitor PD98089
or the JNK specific inhibitor SP600125 did not affect
ApoBDS-1–induced IL-8 mRNA expression or IL-8 release
(Figure 4E and 4F). In contrast, blockade of p38 with
SB203580 resulted in 90% reduction of IL-8 mRNA and
protein (Figure 4E and 4F). These data show that p38-MAPK
is the critical signaling mechanism underlying ApoBDS-1–
induced IL-8 production.
ApoBDS-1 Elicits Inflammatory Responses in
Atherosclerotic Lesions
To determine the relevance of ApoBDS-1 to inflammation in
atherosclerosis, we established an ex vivo atherosclerotic
model using fresh atherosclerotic plaque tissue from human
carotid arteries. Eight plaques were stimulated with 2 con-
centrations of ApoBDS-1, and levels of inflammatory medi-
ators were measured 24 hours later.
The ex vivo cultured plaques released high levels of IL-8,
IL-6, and CCL5 in an unstimulated condition (Figure 5A).
Notably, ApoBDS-1 increased the production of IL-8 and
IL-6 but not CCL5 (Figure 5A), consistent with the responses
of in vitro treated PBMCs (Figure 3).
Furthermore, ApoBDS-1 triggered a dose-dependent pro-
duction of the proinflammatory prostaglandin E2 (PGE2)
(Figure 5A), concomitant with a significant upregulation of
microsomal prostaglandin E2 synthase (mPGES-1) mRNA
(Figure 5B) and IL-8 in plaques (Figure 5B). However,
expressions of cyclooxygenase-1, cyclooxygenase-2, or the
PGE2 receptors EP2, EP3, or EP4 were not greatly altered
(Figure 5B).
ApoBDS-1–Positive Peptides Are Present in
Carotid Atherosclerotic Plaques
To further establish the relevance of ApoBDS-1 to athero-
sclerosis, we verified whether ApoBDS-1 exists in athero-
sclerotic lesions. For this purpose, we made an antibody that
shows definitive specificity to ApoBDS-1 (Figure I in the
online-only Data Supplement) and analyzed ApoBDS-1 in
vivo by immunostaining. As shown in Figure 6A, abundant
ApoBDS-1 signals were observed in extracellular and intra-
cellular spaces in atherosclerotic specimens of human carotid
A
B
Control
12.5 µg/ml
25.0 µg/ml
50.0 µg/ml
Control
12,5 µg/ml
25.0 µg/ml
50.0 µg/ml
6 h
1
10
100
1000
10000
pg
/m
l
24 h
1
10
100
1000
10000
pg
/m
l
IL-6 IL-8 IL-1β CXCL10 IL-10 CCL5 CCL2 TNFα IL-12p70 IFNγ CXCL9
IL-6 IL-8 IL-1β CXCL10 IL-10 CCL5 CCL2 TNFα IL-12p70 IFNγ CXCL9
***
*
***
**
***
*
*
*
Figure 3. Apolipoprotein B100 danger-
associated signal 1–induced soluble medi-
ators. Peripheral blood mononuclear cells
(2.5105) were incubated with 3 concen-
trations of apolipoprotein B100 danger-
associated signal 1 for 6 hours (A) or 24
hours (B). Supernatant interleukin (IL)-6,
IL-8, IL-1, CXCL10, IL-10, CCL5, CCL2,
tumor necrosis factor (TNF)-, IL-12p70,
interferon (IFN)-, and CXCL9 were mea-
sured by cytometric bead array. Data are
meanSEM. *P0.05, **P0.01,
***P0.001compared with control.
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artery. The specificity of the observed ApoBDS-1 signals was
confirmed by competitive blocking with the use of
ApoBDS-1 peptide (Figure 6B and 6C). Of note, the intra-
cellular ApoBDS-1 signal was predominantly colocalized
with CD68 positive macrophages (Figure 6D), occasionally
with smooth muscle cells (Figure 6E), but was not found in
endothelial cells (Figure 6F). These results show that
ApoBDS-1–containing peptides are present in atherosclerotic
lesions.
Evidence of Low-Molecular-Weight
ApoBDS-1–Positive Peptides in
Atherosclerotic Plaques
To further characterize the endogenous ApoBDS-1 peptides,
plaque homogenates were analyzed. Western blot analysis of
denatured plaque proteins showed that ApoBDS-1 peptides
are present in different molecular weights in vivo (Figure
7A). Two small ApoBDS-1 peptide fragments (ie, 40 and
15 kDa in molecular weight) were noted in all tested plaques.
Separation of plaque homogenates in nonreducing condition
by size-exclusion chromatography followed by detection of
ApoBDS-1 with the use of the anti-ApoBDS-1 antibody
confirmed that a major portion of ApoBDS-1 peptides exists
in vivo in molecular weights ranging between 10 and 42 kDa
(Figure 7B).
Low-Molecular-Weight Endogenous
ApoBDS-1–Positive Fractions Contain
ApoBDS-1–Specific Capacity to Trigger
IL-8 Production
Finally, we investigated whether the peptides isolated from
plaque carry the bioactivity of ApoBDS-1. PBMCs were
incubated with 7 ApoBDS-1–positive chromatographic frac-
tions corresponding to the calibrated molecular weight 10 to
42 kDa. In accordance, all 7 fractions significantly enhanced
IL-8 production (Figure III in the online-only Data
Supplement).
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Figure 4. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) induces calcium flux and mitogen-activated protein kinase
phosphorylation. A and B, Peripheral blood mononuclear cells (1106) were stimulated with ApoBDS-1 (25 g/mL) or positive control
calcium ionophore (2.5 mol/L) in the presence of calcium dye (Fluo-4 AM). Increased calcium flux was recorded within 240 seconds
by fluorescence microscopy (A) and a fluorescence reader (B). Medium alone and P265 (25 g/mL), an inactive peptide, were used as
negative controls. Results are representative of 3 independent experiments. C, Peripheral blood mononuclear cells (2.5105) were incu-
bated with ApoBDS-1 (25 g/mL) with or without the calcium chelator 1,2-bis(2-aminophenoxy) ethane-N,N,N,N-tetraacetic acid
(BAPTA). Interleukin (IL)-8 was measured after 24 hours. Data are meanSEM of 4 donors. *P0.05 compared with cells treated with
ApoBDS-1 alone. D, Western blot analysis of ERK1/2, p38, and JNK activation in THP-1 cells stimulated with ApoBDS-1 (25 g/mL).
Results are representative of 4 independent experiments. E and F, The effect of mitogen-activated protein kinase inhibitors on the regu-
lation of IL-8 in peripheral blood mononuclear cells. Peripheral blood mononuclear cells (2.5105) were incubated with ApoBDS-1 (25
g/mL) in the presence or absence of PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), and SP600125 (JNK inhibitor). After 5 and
24 hours, IL-8 was measured by real-time polymerase chain raction (E) and by enzyme immunosorbent assay (F), respectively. Results
are presented as meanSEM of 5 donors. *P0.05, **P0.01compared with cells treated with ApoBDS-1.
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To define the specific ApoBDS-1 activity in these
peptide fractions, the response of IL-8 was determined in
the presence of excess peptide P216c, a truncated
ApoBDS-1 that lacks biological activity (Figure 2G and
Figure IV in the online-only Data Supplement). All 7
fractions were partially blocked to various degrees by
P216c; 1 fraction collected at 49 minutes was overtly
affected, as indicated by a 63% reduction in IL-8 response
in the presence of p216c (Figure 7C). Altogether, these
results imply that peptides with ApoBDS-1 activity can be
found in atherosclerotic plaque.
Discussion
Inflammatory properties of modified LDL contribute to the
development of atherosclerosis.19–21 In this study, we inves-
tigated the relevance of peptides derived from the protein part
of LDL, ApoB100, to the inflammatory response in
atherosclerosis.
By screening a peptide library of human ApoB100, we
have identified a previously unrecognized native peptide
fragment that exhibits distinctive activity triggering inflam-
matory responses in human monocytes/macrophages and
atherosclerotic plaques ex vivo. Importantly, the peptides
with specific ApoBDS-1 activity are present in atherosclero-
sis. Given its capacity to induce innate immune responses, we
named the peptide ApoBDS-1, signifying the first identified
ApoB100-derived danger-associated signal.
ApoBDS-1 has several important properties that contribute
to inflammation in atherosclerosis. The molecular mechanism
that evokes infiltration of leukocytes into the arterial wall is
crucial for the development of atherosclerosis. Our results
indicate that ApoBDS-1 induces the production of a subset of
chemokines that are implicated in the recruitment of mono-
cytes and T lymphocytes in chronic inflammatory diseases,
including atherosclerosis. Furthermore, ApoBDS-1 is a po-
tent stimulus of mPGES-1 pathway, resulting in augmenta-
tion of PGE2 biosynthesis in the atherosclerotic lesion.
Because PGE2 can aggravate the inflammatory response and
evoke progression of atherosclerosis at least in part by
enhancement of vascular oxidative stress, by impairing endo-
thelial function, and by modulation of platelet aggregation
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Figure 5. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) induces inflammatory responses in the supernatant of ex vivo
cultures of atherosclerotic plaques. Fresh atherosclerotic carotid plaques were cut into small pieces and distributed equally in a 48-well
plate (0.1 mg/mL, wt/vol). A, Cultures were stimulated with 25 or 50 g/mL of ApoBDS-1 in duplicate for 24 hours. Interleukin (IL)-8,
IL-6, CCL5, and prostaglandin E2 (PGE2) in supernatant were measured by enzyme-linked immunosorbent assay. *P0.05 compared
with control. B, Cultures were stimulated with 25 g/mL of ApoBDS-1 in duplicate for 24 hours. mRNA levels of microsomal prosta-
glandin E2 synthase (mPGES-1), EP2, EP3, EP4, cyclooxygenase (COX)-1, COX-2, and IL-8 in the plaque tissue were measured by
real-time polymerase chain reaction 24 hours after ApoBDS-1 stimulation. Data are meanSEM of 8 plaque samples. *P0.05 com-
pared with control.
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and arterial thrombosis,22–25 it is likely that ApoBDS-1 has an
important impact on the pathogenic processes of atheroscle-
rosis. In support of this concept, we have shown that
ApoBDS-1 also induces IL-6, another pleiotropic cytokine
with detrimental effects on atherosclerotic plaque develop-
ment.26,27 These bioactivities, as demonstrated in our ex vivo
model of atherosclerosis, link ApoBDS-1 to its pathogenesis.
Whereas ApoBDS-1 induces production of IL-6, IL-8, and
PGE2, it does not trigger expression of potent proinflamma-
tory cytokines, such as IL-1 and tumor necrosis factor-.
This points to a role of ApoBDS-1 in a scenario of low-grade
chronic inflammation. Of note, the in vitro cellular responses
suggest that ApoBDS-1 directly activates monocytes and
macrophages but not T lymphocytes. The molecular mecha-
nism responsible for the cellular specificity, however, needs
further investigation.
These observations postulate a new paradigm for the role
of LDL in atherosclerosis. ApoBDS-1, once it is exposed or
released from ApoB100 of LDL, may act alone or in concert
with oxidized phospholipids as primary danger molecules,
generating signals that recruit inflammatory cells into the
vessel wall and precipitate chronic inflammation in the
atherosclerotic lesion.
The present study has also shed light on signaling path-
ways involved in the peptide-induced activated inflammatory
responses. Our data suggest that there are 2 related signaling
modes that cooperate during ApoBDS-1–induced activation
of monocytes/macrophages. Initially, rapid intracellular Ca2
mobilization occurs on peptide stimulation and appears to be
indispensable for the induction of IL-8. Subsequently, the
peptide activates MAPKs, including ERK, JNK, and p38. Of
the MAPKs, p38-MAPK acts as the principal signaling
mechanism of the induced IL-8 expression, based on the
effects of the selective p38 inhibitor. Moreover, ERK1/2
activation seems to be involved in the regulation of IL-8
secretion. These findings suggest that 2 signaling pathways,
involving Ca2 and MAPK, coordinate to regulate IL-8
production in monocytes/macrophages.
Activation of the p38-MAPK pathway by ApoBDS-1
implicates rather broad bioactivities for this peptide in ath-
erosclerosis. p38-MAPK has been shown to induce the
inflammatory mediators tumor necrosis factor-, PGE2,
and IL-6 and also to regulate many cellular processes,
including proliferation, apoptosis, and migration.22,28 This
notion is further supported by the increased response of
IL-6, IL-8, and microsomal prostaglandin E2 synthase-1/
PGE2 in plaques to the peptide stimulation. Because
p38-MAPK is known as the canonical signaling pathway
mediating inflammatory responses induced by oxidized
LDL and oxidized phospholipids,29,30 these studies to-
gether with the present study lead to the perception that
activation of p38-MAPK is likely the central signaling
mechanism responsible for bioactivities of LDL in athero-
sclerosis. The exact transmembrane signaling pathways
through which ApoBDS-1 activates Ca2 and MAPKs are
unknown, and whether there is a specific receptor that
interacts with ApoBDS-1 needs to be determined.
Several lines of evidence demonstrate the involvement
of ApoB100-derived peptides in atherosclerosis. Clinical
studies have identified antibodies that recognize modified
as well as native ApoB100 peptides in association with
disease progression. In fact, some of these peptides ef-
fected immune protection in experimental models of ath-
erosclerosis.31–33 These findings show that the ApoB100
peptide library can be used to recapitulate immune re-
sponses in atherosclerosis.
Three lines of evidence in this study support the concept
that bioactive ApoBDS-1 is present in atherosclerosis. Im-
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Figure 6. Immunofluorescent detection of apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) in human carotid plaques. Fro-
zen sections of human carotid plaques were fixed with acetone and stained with anti-ApoBDS-1 antibody (red) (A) or anti-ApoBDS-1 in
combination with ApoBDS-1 peptide (B) for specificity control; *P0.05 for results of plaques stained with anti-ApoBDS-1 vs plaques
stained with anti-ApoBDS-1 in combination with ApoBDS-1 peptide. C, The intensity of ApoBDS-1 staining in 4 different carotid
plaques was quantified and compared in the presence or absence of ApoBDS-1. Double immunostaining was used for colocalization of
ApoBDS-1 (red) with CD68-positive macrophages (green) (D), smooth muscle cell -actin (green) (E), and von Willebrand factor (green)
(F). Nuclei were visualized with DAPI (blue). In D, inset details ApoBDS-1 colocalization with CD68. Images were acquired at 400
magnification with confocal microscopy.
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munostaining with the use of a specific antibody shows
that abundant ApoBDS-1–positive signals are present in
human carotid plaques. Western blot and size-exclusion
chromatography analysis of plaque homogenates consis-
tently demonstrate that ApoBDS-1– containing fragments
exist in large- and also in small-molecular-weight fractions in
atherosclerotic plaques. Most importantly, some of these
small ApoBDS-1–positive peptide fractions carry specific
ApoBDS-1 activity (ie, the capacity to induce IL-8 secretion
by PBMCs). However, further studies are still needed to
elucidate the sequences and the structures of these bioactive
ApoBDS-1 fractions.
The process of generation of ApoBDS-1 in vivo is still
poorly understood. According to the structural analysis of
ApoB100 protein,34 ApoBDS-1 is in part embedded in the
surface-exposed proline-rich domain 2 of ApoB100 and
should therefore be susceptible to proteolytic cleavage. In-
deed, trypsinization of ApoB100 results in 4 peptides from
the proline-rich domain 2, 1 of which is nearly identical in
sequence to ApoBDS-1.35 Protease activity in atherosclerotic
lesions is high, and abundant lysosomal proteases exist in the
macrophage-rich regions.36–38 Not surprisingly, in atheroscle-
rotic lesions, ApoB100 can be processed by proteases and
reactive oxygen species into various-sized peptide fragments
in plaques, arguing for the fragmentation of ApoB100 as an
inevitable process.39,40 We observed that abundant
ApoBDS-1 staining is colocalized with lesional macrophages
or in the extracellular space in atherosclerotic lesions. How-
ever, whether the featured localization of ApoBDS-1 is
implicated in the process of ApoB100 degradation and
generation of the bioactive peptides needs to be clarified.
In conclusion, our study has identified a novel native
ApoB100-derived peptide that activates monocytes/macro-
phages to secrete cytokines and chemokines. These findings
shed light on the function of LDL as danger signal40 in
atherosclerosis.
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Figure 7. Detection of bioactive apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) peptides generated in vivo. In vivo gener-
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CLINICAL PERSPECTIVE
Accumulated low-density lipoprotein particles in arterial wall are the primary cause of atherosclerosis by triggering chronic
vascular inflammation, characterized by local activation of cellular inflammatory responses including lesional macro-
phages. The molecular identities of low-density lipoprotein–derived inflammatory components have been poorly defined.
Apolipoprotein B100 (ApoB100) is the only unchangeable protein constituent of the low-density lipoprotein particle. Both
clinical and preclinical studies suggest that ApoB100 protein fragments are implicated in modulation of immune responses
in the process of disease development, implying that ApoB100 is not a bystander to the inflammation of atherosclerosis.
In the present study, by screening a peptide library of human ApoB100, we have identified a previously unrecognized
native peptide fragment that exhibits distinctive activity triggering inflammatory responses of human monocytes/macro-
phages and atherosclerotic plaques ex vivo. Given its capacity to induce innate immune responses, we named the peptide
ApoB100 danger-associated signal 1, signifying the first identified ApoB100–derived danger-associated signal. Impor-
tantly, the peptides with specific ApoB100 danger-associated signal 1 activity are present in atherosclerosis. These findings
shed light on the pathobiological role of low-density lipoprotein in atherosclerosis.
Ketelhuth et al Apolipoprotein B100 Danger-Associated Signal 1 2443
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
 
Synthetic ApoB100 peptides 
A library of synthetic peptides of human ApoB100 was used 1. Briefly, 302 peptides 
that encompassed the entire sequence of human ApoB100 protein were synthesized (K.J. 
Ross Petersen AS, Denmark) and numbered consecutively from P1 to P302, starting from 
the N-terminus. Each peptide was 20 amino acids long, in each of which the first 5 amino 
acids overlapped with the C-terminal sequence of the previous peptide and the last 5 amino 
acids overlapped with the N-terminal sequence of the next peptide. A stock solution of the 
peptides was prepared with 10% EtOH in aqueous NaCl (9 mg/ml) or PBS. No 
thiobarbituric acid reactive substances (TBARS) were detected in the preparations. In 
addition, 3 truncated fragments of P216 (ApoBDS-1), referred to as P216a, P216b, and 
P216c, were synthesized and purified identically as peptide ApoBDS-1 (Ross Petersen AS, 
Denmark). 
Endotoxin levels in the synthetic peptides never exceeded 50 pg/mg of peptide, as 
determined by Limulus amoebocyte lysate detection assay (Associates of Cape Cod, Inc., 
Woods Hole, MA, USA).  
 
Isolation and culture of human PBMCs 
Peripheral blood from healthy volunteers was obtained from the Blood Central of 
Karolinska University Hospital, Stockholm, Sweden. Peripheral blood mononuclear cells 
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(PBMCs) were isolated using Lymphoprep™ gradient medium (density 1.077 g/ml; Axis-
Shield, Oslo, Norway) according to the manufacturer’s instructions. The cells were cultured 
in RPMI that was supplemented with 10% FCS. After 24 h in culture, 2.5 × 105 
PBMCs/well in RPMI with 1% FCS were incubated with the indicated concentrations of 
ApoBDS-1 for 24 h at 37°C, 5% CO2. 
 
Macrophage differentiation in vitro 
PBMCs were cultured in RPMI that was supplemented with 10% FCS in a dish at 
1.5 x 105 cells/cm2. After a 1-h adherence step, floating cells were discarded. Adherent 
monocytes were used to generate macrophages, as described 2. Briefly, monocytes were 
cultured for 7 days in medium that contained 60% AIM V®  (Gibco Invitrogen, Carlsbad, 
CA, USA) and 30% Iscove's Modified Dulbecco's Medium (IMDM, Gibco Invitrogen, 
Carlsbad, CA, USA) and was supplemented with 10% inactivated AB+ serum on dishes. 
The media was changed after 3 days. After differentiation, the cells were scraped, 
resuspended in RPMI that was supplemented with 10% FCS, and allowed to rest. After 24 
h of rest, 2.5 × 105 macrophages/ml were plated in RPMI with 1% FCS and incubated with 
25 µg/ml ApoB-DS1 for 24 h at 37°C, 5% CO2. 
 
Stable TLR4 transfectants 
HEK-293/TLR4 cells (stably transfected with human TLR4A, MD-2, and CD14, 
Invivogen, San Diego, CA, USA) were grown in DMEM with 10% FCS, HygroGold™ (50 
g/ml), Normocin™ (100 g/ml), and blasticidin (10 g/ml) and seeded at 1 x 104 cells per 
well. Cells were stimulated with LPS (100 ng/ml) or ApoBDS-1 (50 µg/ml) and incubated 
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overnight at 37°C, 5% CO2. IL-8 concentrations in the supernatants were measured by 
ELISA. 
 
Cytokine and chemokine measurements  
TNF-α, IL-1β, IL-6, IL-10, IL-12p40, IFN-γ, IP-10, MIG, IL-8, CCL2 (MCP-1), 
and CCL5 (RANTES) in the supernatants of PBMC and plaque tissue cultures were 
measured by Cytometric Bead Array (CBA®, BD Bioscience, CA, USA) or ELISA (R&D 
Systems, Abingdon, United Kingdom), following the manufacturer’s protocol. 
Prostaglandin E2 (PGE2) in the supernatants of PBMC and plaque tissue cultures was 
measured using the PGE2 Express EIA Kit (Cayman Europe, Tallin, Estonia) per the 
manufacturer's instructions. 
 
RNA analysis 
RNA extraction and reverse-transcription were performed as described 3. 
Quantitative real time-PCR analysis was performed on an ABI Prism 7900 HT Sequence 
Detector (Applied Biosystems, Foster City, CA, USA) using Assay-on-Demand primers 
and probes (Applied Biosystems, Foster City, CA, USA). mRNA levels were normalized to 
the housekeeping genes β-2 macroglobulin and GAPDH. Relative expression was 
determined by the 2-ΔΔCT method 4. 
 
Analysis of calcium flux 
PBMCs were resuspended at 1 x 106 cells/ml in Hanks’ balanced saline solution 
(HBSS), containing calcium, 1% (v/v) FCS, 5 µM Fluo-4 AM (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA), and 2.5 mM probenecid (Molecular Probes, Invitrogen, 
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Carlsbad, CA, USA). After a 30 min pre-incubation at 37ºC, the cells were washed with 
calcium-free HBSS and incubated with 25 µg/ml ApoBDS-1 or 2.5 μM calcium ionhophore 
as a positive control. Increased calcium flux was recorded within 240 seconds, as indicated 
in the figures. Samples were excited at 485 nm, and emission spectra were recorded at 535 
nm by fluorescence microscopy or on a 96-well plate fluorescence reader (Fluoroskan 
Ascent FL, Thermo Scientific). Data are presented as fold-increase compared with baseline 
readings from cells in medium alone. 
 
Detection of MAPK phosphorylation 
To examine MAPK responses, THP-1 cells were stimulated with 25 μg/mL 
ApoBDS-1 for the indicated times. Next, the cells were washed with cold PBS, and lysates 
were generated by homogenizing the cells in RIPA lysis buffer (1% Nonidet® P40, 50 mM 
Tris, pH 8.0, 150 mM NaCl, deoxycholate 0,5%, SDS 0.1%) supplemented with protease 
inhibitor cocktail (Complete™, Roche, Basel, Switzerland) and phosphatase inhibitors (10 
mM sodium fluoride and 1 mM sodium orthovanadate, Sigma-Aldrich, St. Louis, MO, 
USA). 
Equal amounts of proteins (30 µg) were separated by SDS-PAGE (4.0% - 15%, Bio-
Rad, Richmond, CA, USA) and transferred to a PVDF membrane (GE Healthcare, Uppsala, 
Sweden). After being blocked with 5% nonfat dry milk, phosphorylated and total proteins 
were detected using monoclonal antibodies to ERK1/2, phospho-ERK1/2, p38, phospho-
p38, JNK, and phospho-JNK (Cell Signaling Technology, Beverly, MA, USA). The blots 
were incubated with HRP-conjugated anti-rabbit IgG (Dako, Glostrup, Denmark) and 
developed by ECL (GE Healthcare, Uppsala, Sweden).  
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Blocking of MAPK signaling pathways 
For pharmacological inhibition of ERK1/2, p38-MAPK, and JNK, PD98059 (10 
M), SB203580 (10 M), and SP600125 (40 M) (all purchased from Calbiochem, 
Darmstadt, Germany) were added 30 min before the PBMCs were stimulated with peptides. 
The inhibitors were dissolved in 100% dimethylsulphoxide (DMSO); the final 
concentration of DMSO in the cultures was < 0.1%. Unstimulated cell cultures that were 
incubated with 0.1% DMSO were included as a control and did not experience any 
biological effects (data not shown). 
 
Anti-ApoBDS-1 specificity analysis. 
Specificity of anti-ApoBDS-1 rabbit polyclonal IgG antibody against ApoBDS-1 
was evaluated by ELISA. Briefly, 50 µL of the different antigens (1 µg/ml in 
Carbonate/Bicarbonate pH 9.5) was added to 96-well ELISA plates and incubated 
overnight at 4°C. Coated plates were washed with PBS and blocked with 1% gelatin (Gibco 
Invitrogen, Carlsbad, CA, USA) in PBS for 1 hr at room temperature. Next, plates were 
washed and incubated for 2 additional hours with anti-ApoBDS-1 antibody diluted 1:1000 
in Tris-buffered saline (TBS)/gelatin 0.1%. After washing, total IgG levels were measured 
using enzyme-conjugated goat anti-rabbit antibodies (Dako, Glostrup, Denmark). The 
plates were washed, and colorimetric reactions were developed using TMB (3,3’,5,5’-
Tetramethylbenzidine, BD Biosciences, Franklin Lakes, NJ, USA). The absorbance was 
measured using a microplate reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA).   
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Supplemental figure legends 
 
Supplemental figure I. Anti-ApoBDS-1 antibody specificity analysis.    
Specific reactivity of anti-ApoBDS-1 rabbit polyclonal IgG antibody to the ApoB100 
peptides, ApoB100 protein, native LDL, and oxLDL was evaluated by ELISA. Values are 
expressed as mean ± SEM of the OD at 450 nm.  
 
Supplemental figure II.  Molecular weight calibration of Superose 6/Discovery BIO 
GFC-500. 
Molecular weight calibration of the coupled columns Superose 6 and Discovery BIO GFC-
500 was performed using LMW and HMW protein cocktails from GE Healthcare, Uppsala, 
Sweden. Samples fractionated at a flow rate of 0.4 mL/min, using Ammonium bicarbonate 
buffer, pH 7.4. Thyroglobulin 669 kDa; Ferritin 440 kDa; Catalase 232 kDa; Lactate 
dehydrogenase 140 kDa; Albumin 66 kDa; Carbonic Anhydrase 29 kDa; Ribonuclease A 
13.7 kDa;  Aprotinin 6.5 kDa. X axis, retention time; Y axis, molecular weight (kDa). 
   
Supplemental figure III. Assessment of lL-8 production in response to low molecular 
weight ApoBDS-1 positive fractions from plaque homogenates.  
2 x 105 PBMCs were stimulated with low molecular weight fractions (10 to 42 kDa) from 2 
different plaque homogenates. ApoBDS-1 (50 µg/ml) was used as positive control (black 
bar), and medium alone as negative control (grey bar). IL-8 was measured after 24h. Data 
are means ± SEM of IL-8 levels of 4 experiments. *) P<0.05; **) P<0.01 for samples vs 
negative control. 
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Supplemental figure IV. Blockade of ApoBDS-1 induced IL-8 release from PBMCs by 
truncated ApoBDS-1 peptides. 
2 x 105 PBMCs were stimulated with ApoBDS-1 (25 µg/ml) or in combination with 5-fold 
molar excess of truncated ApoBDS-1 peptides P216a, P216b, or P216c. LPS (100 ng/ml) 
was used as positive control, and medium as negative control. IL-8 was measured after 24 h 
incubation. Truncated peptides are able to specifically block ApoBDS-1 induced IL-8 
release. Data are presented as means ± SEM of IL-8 levels. *) P<0.05. The data are 
representative of 2 experiments.   
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